The Resource Cancer pharmacology and pharmacotherapy review : study guide for oncology boards and MOC exams, Francis P. Worden, Anthony J. Perissinotti, Bernard L. Marini

Cancer pharmacology and pharmacotherapy review : study guide for oncology boards and MOC exams, Francis P. Worden, Anthony J. Perissinotti, Bernard L. Marini

Label
Cancer pharmacology and pharmacotherapy review : study guide for oncology boards and MOC exams
Title
Cancer pharmacology and pharmacotherapy review
Title remainder
study guide for oncology boards and MOC exams
Statement of responsibility
Francis P. Worden, Anthony J. Perissinotti, Bernard L. Marini
Creator
Contributor
Author
Subject
Genre
Language
eng
Summary
Cancer Pharmacology and Pharmacotherapy Review is the first book devoted entirely to providing the 'must-know' facts on each cancer agent including their pharmacokinetics, FDA-approved indications, toxicity, interactions, and other important information that is commonly found on board examinations and essential for any clinician or practitioner to review . The authors, an oncologist and two pharmacists, have developed a handy question-and-answer format to present the material in digestible bursts. As the pharmacology section continues to represent a major portion of the medical oncology exam and a key component on oncology MOC exams, this portable study guide will help prepare anyone looking to fine-tune their knowledge on cancer drugs before the test. Not to mention, with recent advancements in the field of cancer treatment, it has become more cumbersome to recall and maintain essential knowledge of every cancer therapeuticómaking this book not only an exam resource but also a handy quick reference for oncologists and pharmacists alike. Key Features: Conveniently organized and arranged by drug class and subtypes for easier recall and classification Includes proper dosage adjustments to account for liver and kidney dysfunction. Features tables throughout that provide quick reference regarding FDA-approved medications Simplified diagrams and illustrations facilitate the pharmacokinetic processes
Cataloging source
N$T
Dewey number
615.7/98076
Illustrations
illustrations
Index
index present
LC call number
RS431.A64
Literary form
non fiction
Nature of contents
dictionaries
Label
Cancer pharmacology and pharmacotherapy review : study guide for oncology boards and MOC exams, Francis P. Worden, Anthony J. Perissinotti, Bernard L. Marini
Publication
Note
Includes index
Antecedent source
unknown
http://library.link/vocab/branchCode
  • net
Carrier category
online resource
Carrier category code
cr
Carrier MARC source
rdacarrier
Color
multicolored
Content category
text
Content type code
txt
Content type MARC source
rdacontent
Contents
  • Cover; Title; Copyright; Contents; List of Figures; List of Tables; Preface; Share Cancer Pharmacology and Pharmacotherapy Review: Study Guide for Oncology Boards and MOC Exams; Part I: Traditional Chemotherapy; Chapter 1: Microtubule Inhibitors; Taxanes and Related Agents; Vinca Alkaloids; Chapter 2: Alkylating Agents; Nitrogen Mustards; Non-Nitrogen Mustards; Platinums; Antitumor Antibiotics; Chapter 3: Enzyme Inhibitors-Topoisomerase I Inhibitors; Camptothecans; Chapter 4: Enzyme Inhibitors-Topoisomerase II Inhibitors; Epipodophyllotoxins; Anthracyclines; Chapter 5: Antimetabolites
  • AntifolatesPurine Antagonists; Purine Analogues; Pyrimidine Analogues/Fluoropyrimidines; Pyrimidine Analogues/Deoxycytidine Analogues; Part II: Next-Generation Antineoplastics; Chapter 6: Monoclonal Antibodies; Chapter 7: VEGF Trap; Ziv-Aflibercept (Zaltrap®); Chapter 8: Tyrosine Kinase Inhibitors; Angiogenesis Inhibitors and Multi-Kinase Inhibitors; Breakpoint Cluster Region-Abelson Murine Leukemia Viral Oncogene Homolog 1 (BCR-ABL) Inhibitors; B-Cell Receptor (BCR) Pathway Inhibitors; EGFR-Ras-Raf-MEK-ERK (MAPK) Pathway Inhibitors; Miscellaneous Oral Targeted Therapies
  • Appendix A: Agents Requiring Renal and/or Hepatic Dose AdjustmentsAppendix B: Extravasation Risk of Chemotherapeutic Agents; Index
  • Chapter 9: Antiandrogen TherapiesChapter 10: Mammalian Target of Rapamycin (mTOR) Inhibitors; Chapter 11: Histone Deacetylase (HDAC) Inhibitors; Chapter 12: Hypomethylating Agents; Chapter 13: Proteasome Inhibitors; Chapter 14: Immunomodulatory Agents; Chapter 15: L-Asparaginase Enzymes; Chapter 16: Promyelocytic Leukemia Gene Retinoic Acid Receptor-Alpha (PML-RARÜ) Translocation Inhibitors; Part III: Miscellaneous Oncolytics; Chapter 17: Sipuleucel-T (Provenge®); Chapter 18: Omacetaxine (Synribo®); Chapter 19: Estramustine (Emcyt®)
Control code
ocn942588609
Dimensions
unknown
Extent
1 online resource (xiv, 189 pages)
File format
unknown
Form of item
online
Isbn
9781617052521
Media category
computer
Media MARC source
rdamedia
Media type code
c
Other physical details
color illustrations
Quality assurance targets
unknown
http://library.link/vocab/recordID
.b34507127
Sound
unknown sound
Specific material designation
remote
System control number
  • (OCoLC)942588609
  • ebl1617052523

Library Locations

    • Deakin University Library - Geelong Waurn Ponds CampusBorrow it
      75 Pigdons Road, Waurn Ponds, Victoria, 3216, AU
      -38.195656 144.304955
Processing Feedback ...